BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35181635)

  • 1. ETV2 regulates PARP-1 binding protein to induce ER stress-mediated death in tuberin-deficient cells.
    Shrestha S; Lamattina A; Pacheco-Rodriguez G; Ng J; Liu X; Sonawane A; Imani J; Qiu W; Kosmas K; Louis P; Hentschel A; Steagall WK; Onishi R; Christou H; Henske EP; Glass K; Perrella MA; Moss J; Tantisira K; El-Chemaly S
    Life Sci Alliance; 2022 May; 5(5):. PubMed ID: 35181635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor type 1 blockade regulates Klotho expression to induce TSC2-deficient cell death.
    Shrestha S; Adib E; Imani J; Aguiar DJ; Lamattina AM; Tassew DD; Henske EP; Perrella MA; Priolo C; El-Chemaly S
    J Biol Chem; 2022 Nov; 298(11):102580. PubMed ID: 36220392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.
    Li C; Liu X; Liu Y; Zhang E; Medepalli K; Masuda K; Li N; Wikenheiser-Brokamp KA; Osterburg A; Borchers MT; Kopras EJ; Plas DR; Sun J; Franz DN; Capal JK; Mays M; Sun Y; Kwiatkowski DJ; Alayev A; Holz MK; Krueger DA; Siroky BJ; Yu JJ
    Mol Cancer Res; 2017 Oct; 15(10):1318-1330. PubMed ID: 28710231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
    Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
    Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway.
    Feng Y; Li T; Li Y; Lin Z; Han X; Pei X; Zhang Y; Li F; Yang J; Shao D; Li C
    Clin Transl Med; 2023 Jul; 13(7):e1333. PubMed ID: 37478294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
    Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
    Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis.
    Sun Y; Zhang E; Lao T; Pereira AM; Li C; Xiong L; Morrison T; Haley KJ; Zhou X; Yu JJ
    Horm Cancer; 2014 Oct; 5(5):284-98. PubMed ID: 25069840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
    Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
    Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC1 activation in lung mesenchyme drives sex- and age-dependent pulmonary structure and function decline.
    Obraztsova K; Basil MC; Rue R; Sivakumar A; Lin SM; Mukhitov AR; Gritsiuta AI; Evans JF; Kopp M; Katzen J; Robichaud A; Atochina-Vasserman EN; Li S; Carl J; Babu A; Morley MP; Cantu E; Beers MF; Frank DB; Morrisey EE; Krymskaya VP
    Nat Commun; 2020 Nov; 11(1):5640. PubMed ID: 33159078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting SPHK1/S1PR3-regulated S-1-P metabolic disorder triggers autophagic cell death in pulmonary lymphangiomyomatosis (LAM).
    Li F; Zhang Y; Lin Z; Yan L; Liu Q; Li Y; Pei X; Feng Y; Han X; Yang J; Zheng F; Li T; Zhang Y; Fu Z; Shao D; Yu J; Li C
    Cell Death Dis; 2022 Dec; 13(12):1065. PubMed ID: 36543771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
    Siroky BJ; Yin H; Babcock JT; Lu L; Hellmann AR; Dixon BP; Quilliam LA; Bissler JJ
    Am J Physiol Renal Physiol; 2012 Sep; 303(6):F831-44. PubMed ID: 22791333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
    Huang J; Wu S; Wu CL; Manning BD
    Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen activates pyruvate kinase M2 and increases the growth of TSC2-deficient cells.
    Lu Y; Liu X; Zhang E; Kopras EJ; Smith EP; Astreinidis A; Li C; Leung YK; Ho SM; Yu JJ
    PLoS One; 2020; 15(2):e0228894. PubMed ID: 32078667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex.
    Kovalenko A; Sanin A; Kosmas K; Zhang L; Wang J; Akl EW; Giannikou K; Probst CK; Hougard TR; Rue RW; Krymskaya VP; Asara JM; Lam HC; Kwiatkowski DJ; Henske EP; Filippakis H
    Cancer Res; 2021 Apr; 81(8):2086-2100. PubMed ID: 33593821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberin regulates E-cadherin localization: implications in epithelial-mesenchymal transition.
    Barnes EA; Kenerson HL; Jiang X; Yeung RS
    Am J Pathol; 2010 Oct; 177(4):1765-78. PubMed ID: 20813961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TSC1 and TSC2 tumor suppressors are required for proper ER stress response and protect cells from ER stress-induced apoptosis.
    Kang YJ; Lu MK; Guan KL
    Cell Death Differ; 2011 Jan; 18(1):133-44. PubMed ID: 20616807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.